Latest news with #Unloxcyt
Mint
01-08-2025
- Business
- Mint
Sun Pharma shares fall 5.7% post Q1 results: What should investors do now?
Sun Pharmaceutical Industries saw its shares tumble by 5.7 percent to an intraday low of ₹ 1,608.30 on the BSE on Friday, following the announcement of its first-quarter results for FY26. The stock's decline was largely triggered by a sharp 20 percent year-on-year fall in consolidated net profit to ₹ 2,278 crore for the June 2025 quarter, compared to ₹ 2,836 crore in the same quarter last year. On a sequential basis, however, net profit rose 6 percent from ₹ 2,150 crore reported in the March 2025 quarter. Adding to the negative sentiment was the fact that several brokerages revised their target prices downward for the pharma major. Despite the profit drop, Sun Pharma posted a healthy top-line performance. The consolidated revenue grew over 9 percent year-on-year to ₹ 13,851 crore, driven by solid momentum across its key markets—including India, the US, and Rest of World (ROW) geographies. EBITDA rose by 19.2 percent to ₹ 4,302 crore, with margins expanding to 31.1 percent from 28.5 percent in the same period last year. Commenting on the performance, Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said the company delivered a strong quarter with consistent growth across markets. 'India continues to show strong momentum, contributing meaningfully to the overall performance. The U.S. launch of LEQSELVI is a significant milestone, expanding our dermatology portfolio and strengthening our Innovative Medicines business,' he said. Brokerages React: Trimming Targets, Watching Specialty Growth HDFC Securities lowered its FY26 and FY27 EPS estimates by 7 percent and 6 percent respectively and cut the target price to ₹ 1,960, valuing the stock at 33x Q1FY28E EPS. While it expects strong momentum in the specialty segment—including a ramp-up in Leqselvi and launch of Unloxcyt—HDFC Sec noted that increased investment spending of USD 100 million starting Q2FY26 and a 25 percent tax guidance were negatives. However, it maintained a positive outlook on India formulations and continued R&D spends (6–8 percent of sales), expecting a mid- to high-single-digit revenue growth trajectory and stable EBITDA expansion. JM Financial maintained a 'Buy' rating with a target price of ₹ 1,999. The brokerage termed Sun Pharma's Q1FY26 performance strong due to a better product mix and lower cost of goods sold. JM highlighted robust 14 percent YoY growth in India business and 17 percent growth in global specialty. While US generics remained under pressure, exports from Emerging Markets and ROW remained firm. The brokerage expects the new specialty launches, such as Leqselvi and Unloxcyt, alongside expansion of Ilumya and Winlevi, to drive the next leg of growth. Sun Pharma is projected to clock an 11 percent revenue CAGR over FY25–FY28, supported by a healthy cash balance of USD 3.5 billion and continued focus on oncology, ophthalmology, and dermatology. Motilal Oswal Financial Services reduced its target price to ₹ 1,960 from ₹ 2,000, while maintaining a 'Buy' call. The brokerage expects Sun Pharma's innovative and branded portfolio to continue providing earnings support, although it trimmed FY26 and FY27 EPS estimates by 5 percent and 4 percent respectively due to higher operating costs and tax outgo. It believes regulatory clarity on US tariffs remains a key monitorable but sees recent launches like Leqselvi and Ilumya pipeline filings boosting the company's specialty segment. It anticipates a 14 percent CAGR in earnings through FY27. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
01-06-2025
- Business
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
01-06-2025
- Business
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
Time of India
01-06-2025
- Business
- Time of India
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Synopsis Sun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D spending to be 6-8% of sales.
New Indian Express
31-05-2025
- Business
- New Indian Express
Sun Pharma's Checkpoint buy: Why it's a strategic fit in the new SPIL focus
CHENNAI: India's largest drug maker, Sun Pharmaceutical Industries, has completed its acquisition of US-based Checkpoint Therapeutics for approximately $355 million. This strategic move significantly strengthens Sun Pharma's oncology and dermatology portfolio, aligning with its focus on high-value specialty therapies. Despite the long-term strategic value, the market reaction on Friday surprised many, as Sun Pharma's share price fell by 1.46% at the close of the week's trading. This dip may have been driven by immediate concerns, including regulatory issues at a key manufacturing facility and the company's cautious financial guidance. Investors are closely monitoring developments—particularly the US FDA's observations regarding Sun Pharma's Dahej facility. The company's financial performance in the coming quarters will also be under scrutiny as stakeholders assess the potential impact on its stock trajectory. Strategic Rationale and Synergies of the Checkpoint Deal Drug industry analysts believe the Checkpoint acquisition is a major strategic gain for Sun Pharma, which has historically grown through carefully chosen, high-potential acquisitions. According to analysts at HDFC Securities, the deal aligns with Sun Pharma's capital allocation strategy to strengthen its specialty business. Checkpoint's Unloxcyt—a novel skin cancer drug—will serve as a complementary addition to its oncology portfolio. In the post-Q4 earnings call, Chairman and Managing Director Dilip Shanghvi reiterated the company's commitment to expanding its specialty business. Sun Pharma's specialty and innovative therapeutics division currently focuses on dermatology, ophthalmology, and oncology. Unloxcyt will complement existing products such as Odomzo (sonidegib) and Yonsa (abiraterone acetate)—both approved in the US—Nidlegy (awaiting approval in the EU), and the recently acquired Fibromun (in Phase III trials). Other specialty molecules in development, including Ilumya (for psoriatic arthritis), GL0034 (obesity), MM-II (osteoarthritis), SCD-044 (atopic dermatitis/psoriasis), and Fibromun (for soft tissue sarcoma/glioblastoma), offer long-term growth potential. According to analysts, the Checkpoint acquisition is strategically significant for four key reasons:
